Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | THRB | P10828 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | CPA1 | P15085 | 2/20 | 0.49 |
| ▸ | CPA3 | P15088 | 2/20 | 0.49 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.49 |
| ▸ | CPB1 | P15086 | 1/20 | 0.49 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.49 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL117431 | 0.86 | CYP1A2 (0.60) | ALDH1A1THRBCYP2C9CYP2C19HSD17B10 | |
| SCHEMBL23551743 | 0.85 | ALDH1A1 (0.55) | ALDH1A1THRBCYP2C9CYP2C19HSD17B10 | |
| SCHEMBL23552087 | 0.85 | ALDH1A1 (0.55) | ALDH1A1THRBCYP2C9CYP2C19HSD17B10 | |
| SCHEMBL23552039 | 0.85 | ALDH1A1 (0.55) | ALDH1A1THRBCYP2C9CYP2C19HSD17B10 | |
| SCHEMBL8106533 | 0.85 | CYP1A2 (0.59) | ALDH1A1THRBCYP2C9CYP2C19HSD17B10 | |
| SCHEMBL23552058 | 0.84 | ALDH1A1 (0.50) | ALDH1A1THRBCYP2C9CYP2C19HSD17B10 | |
| SCHEMBL23552106 | 0.84 | ALDH1A1 (0.50) | ALDH1A1THRBCYP2C9CYP2C19HSD17B10 | |
| SCHEMBL3184765 | 0.84 | PPARG (0.57) | ALDH1A1CYP1A2KMT2AMEN1CPA1 | |
| SCHEMBL1914987 | 0.84 | CPA1 (0.66) | CYP1A2KMT2AATMCPA1CPA3 | |
| SCHEMBL4240908 | 0.84 | CYP1A2 (0.53) | ALDH1A1THRBCYP2C9CYP2C19HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105102603-B | Improvement related with fabric conditioner | 荷兰联合利华有限公司 | 2018-08-07 | — | — | CN | disclosed |
| CN-104968325-B | With improved beautiful and sensory quality composition | 荷兰联合利华有限公司 | 2018-07-20 | — | — | CN | disclosed |
| CN-104302750-B | The improvement related with fabric conditioner | 荷兰联合利华有限公司 | 2018-06-19 | — | — | CN | disclosed |
| US-20100016285-A1 | HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2010-01-21 | — | — | US | disclosed |
| EP-2128157-A1 | HETEROCYCLIDENE-N-(ARYL)ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-02 | — | — | EP | disclosed |
| CN-101589038-A | Heterocyclidene-N-(aryl)acetamide derivative | MOCHIDA PHARM CO LTD (JP) | 2009-11-25 | — | — | CN | disclosed |
| EP-0906901-B1 | Process for producing propionic acid derivatives | AJINOMOTO KK (JP) | 2002-03-27 | — | — | EP | disclosed |
| US-6242635-B1 | THROUGH SHORT SYNTHESIS ROUTE INDUSTRIALLY SAFE AND EASILY; USED IN PRODUCING OPTICALLY ACTIVE SUBSTANCE CONVERTIBLE INTO A LENIN INHIBITOR INTERMEDIATE, ENKEPHALINASE INHIBITOR, OR PROTEASE INHIBITOR | AJINOMOTO CO., INC. (JP) | 2001-06-05 | — | — | US | disclosed |
| EP-0906901-A2 | Process for producing propionic acid derivatives | Ajinomoto Co., Inc. (JP) | 1999-04-07 | — | — | EP | disclosed |
| CN-1041418-C | Xanthine derivatives as adenosine A1 receptor antagonists | MERRELL DOW PHARMA (US) | 1998-12-30 | — | — | CN | disclosed |
| US-5840729-A | ATTENUATING COGNITIVE DEFICIT | MERRELL PHARMACEUTICALS INC. (US) | 1998-11-24 | — | — | US | disclosed |
| EP-0686155-B1 | XANTHINE DERIVATIVES AS ADENOSINE A1 RECEPTOR ANTAGONISTS | MERRELL PHARMA INC (US) | 1998-07-29 | — | — | EP | disclosed |
| EP-0449175-B1 | Selective adenosine receptor agents | MERRELL PHARMA INC (US) | 1997-07-30 | — | — | EP | disclosed |
| CN-1032815-C | Selective adenosine receptor agents | MERRELL DOW PHARMA (US) | 1996-09-18 | — | — | CN | disclosed |
| CN-1118599-A | Xanthine derivatives as adenosine A1 receptor antagonists | MERRELL DOW PHARMA (US) | 1996-03-13 | — | — | CN | disclosed |
| EP-0686155-A1 | XANTHINE DERIVATIVES AS ADENOSINE A1 RECEPTOR ANTAGONISTS | MERRELL PHARMACEUTICALS INC. (US) | 1995-12-13 | — | — | EP | disclosed |
| WO-1994019349-A1 | XANTHINE DERIVATIVES AS ADENOSINE A1 RECEPTOR ANTAGONISTS | MERRELL DOW PHARMACEUTICALS INC. (US) | 1994-09-01 | — | — | WO | disclosed |
| CN-1055181-A | SELECTIVE ADENOSINE RECEPTOR AGENTS | MERRELL DOW PHARMA (US) | 1991-10-09 | — | — | CN | disclosed |
| EP-0449175-A2 | Selective adenosine receptor agents | MERRELL PHARMACEUTICALS INC. (US) | 1991-10-02 | — | — | EP | disclosed |
| US-5047534-A | Xanthine derivatives; hyupotensive agents, cardiotonic agents | MERRELL DOW PHARMACEUTICALS INC. (US) | 1991-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016285-A1 | HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE | CCNY, CCND3, NSD3 | ALDH1A1 1904/4885THRB 2282/4885CYP2C9 297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.